αvβ3 integrin-targeted peptide/peptidomimetic-drug conjugates: In-depth analysis of the linker technology

Current Topics in Medicinal Chemistry

Volumn 16, Issue 3, 2016, Pages 314-329

  Dal Corso, Alberto ^a   Pignataro, Luca ^a   Belvisi, Laura ^a   Gennari, Cesare ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Anticancer prodrugs; Drug targeting; Integrins; Peptidomimetics; RGD; Small molecule drug conjugates

Indexed keywords

ANTIBODY DRUG CONJUGATE; ANTINEOPLASTIC AGENT; ARGINYLGLYCYLASPARTIC ACID; BRENTUXIMAB VEDOTIN; CAMPTOTHECIN; DOXORUBICIN; DRUG ADDITIVE; HYDROLYTICALLY LABILE LINKER; LINKER; MATRIX METALLOPROTEINASE; NAMITECAN; PACLITAXEL; PEPTIDE LINKER; PEPTIDOMIMETIC AGENT; REDUCIBLE LINKER; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; TRASTUZUMAB EMTANSINE; UNCLASSIFIED DRUG; VEDOTIN; VINTAFOLIDE; VITRONECTIN RECEPTOR; ARGINYL-GLYCYL-ASPARTIC ACID; DRUG CARRIER; OLIGOPEPTIDE;

AMINO ACID SEQUENCE; ARTICLE; BINDING COMPETITION; CANCER CHEMOTHERAPY; CLINICAL TRIAL (TOPIC); CYTOTOXICITY; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG STABILITY; DRUG TARGETING; ENDOCYTOSIS; GENE OVEREXPRESSION; HUMAN; LIGAND BINDING; NEOPLASM; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); STEREOSPECIFICITY; ANIMAL; CHEMISTRY; METABOLISM; NEOPLASMS; PATHOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG CARRIERS; HUMANS; INTEGRIN ALPHAVBETA3; NEOPLASMS; OLIGOPEPTIDES; PEPTIDOMIMETICS;

EID: 84945960356     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/1568026615666150701114343     Document Type: Article

References (90)

1. Lammers, T.; Kiessling, F.; Hennink, W. E.; Storm, G. Drug targeting to tumors: Principles, pitfalls and (pre-) clinical progress. J. Control. Release, 2012, 161(2), 175-187.
2. Chari, R. V. J.; Miller, M. L.; Widdison, W. C. Antibody-Drug Conjugates: An Emerging Concept in Cancer Therapy. Angew. Chem. Int. Ed., 2014, 53(15), 3796-3827.
3. Thayer, A. M. Building antibody-drug conjugates. C&EN, 2014, 92(3), 13-21.
4. Van Schouwenburg, P. A.; Bartelds, G. M.; Hart, M. H.; Aarden, L.; Wolbink, G. J.; Wouters, D. A novel method for the detection of antibodies to adalimumab in the presence of drug reveals "hidden" immunogenicity in rheumatoid arthritis patients. J. Immunol. Methods, 2010, 362(1-2), 82-88.
5. Krall, N.; Scheuermann, J.; Neri, D. Small Targeted Cytotoxics: Current State and Promises from DNA-Encoded Chemical Libraries. Angew. Chem. Int. Ed., 2013, 52(5), 1384-1402.
6. Svensen, N.; Walton, J. G. A.; Bradley, M. Peptides for cell-selective drug delivery. Trends Pharmacol. Sci., 2012, 33(4), 186-192.
7. Dyba, M.; Tarasova, N. I.; Michejda, C. J. Small Molecule Toxins Targeting Tumor Receptors. Curr. Pharm. Des, 2004, 10(19), 2311-2334.
8. Krall, N.; Pretto, F.; Decurtins, W.; Bernardes, G. J. L.; Supuran, C. T.; Neri, D. A Small-Molecule Drug Conjugate for the Treatment of Carbonic Anhydrase IX Expressing Tumors. Angew. Chem. Int. Ed., 2014, 53(16), 4231-4235.
9. Vlahov, I. R.; Leamon, C. P. Engineering Folate-Drug Conjugates to Target Cancer: From Chemistry to Clinic. Bioconjug. Chem., 2012, 23(7), 1357-1369.
10. Danhier, F.; Breton, A. L.; Preat, V. RGD-Based Strategies To Target Alpha(v) Beta(3) Integrin in Cancer Therapy and Diagnosis. Mol. Pharm., 2012, 9(11), 2961-2973.
11. Cheng, K.; Kothapalli, S.-R.; Liu, H.; Koh, A. L.; Jokerst, J. V.; Jiang, H.; Yang, M.; Li, J.; Levi, J.; Wu, J. C.; Gambhir, S. S.; Cheng, Z. Construction and Validation of Nano Gold Tripods for Molecular Imaging of Living Subjects. J. Am. Chem. Soc., 2014, 136(9), 3560-3571.
12. Lanzardo, S.; Conti, L.; Brioschi, C.; Bartolomeo, M. P.; Arosio, D.; Belvisi, L.; Manzoni, L.; Maiocchi, A.; Maisano, F.; Forni, G. A new optical imaging probe targeting αVβ3 integrin in glioblastoma xenografts. Contrast Media Mol. Imaging, 2011, 6(6), 449-458.
13. Shi, J.; Wang, L.; Kim, Y.-S.; Zhai, S.; Liu, Z.; Chen, X.; Liu, S. Improving Tumor Uptake and Excretion Kinetics of 99mTc- Labeled Cyclic Arginine-Glycine-Aspartic (RGD) Dimers with Triglycine Linkers. J. Med. Chem., 2008, 51(24), 7980-7990.
14. Kim, M. S.; Lee, D.-W.; Park, K.; Park, S.-J.; Choi, E.-J.; Park, E. S.; Kim, H. R. Temperature-triggered tumor-specific delivery of anticancer agents by cRGD-conjugated thermosensitive liposomes. Colloids Surf. B Biointerfaces, 2014, 116(0), 17-25.
15. Amin, M.; Badiee, A.; Jaafari, M. R. Improvement of pharmacokinetic and antitumor activity of PEGylated liposomal doxorubicin by targeting with N-methylated cyclic RGD peptide in mice bearing C-26 colon carcinomas. Int. J. Pharm., 2013, 458(2), 324-333.
16. Battistini, L.; Burreddu, P.; Sartori, A.; Arosio, D.; Manzoni, L.; Paduano, L.; D'Errico, G.; Sala, R.; Reia, L.; Bonomini, S.; Rassu, G.; Zanardi, F. Enhancement of the Uptake and Cytotoxic Activity of Doxorubicin in Cancer Cells by Novel cRGD-Semipeptide- Anchoring Liposomes. Mol. Pharm., 2014, 11(7), 2280-2293.
17. Arosio, D.; Manzoni, L.; Araldi, E. M. V.; Scolastico, C. Cyclic RGD Functionalized Gold Nanoparticles for Tumor Targeting. Bioconjug. Chem., 2011, 22(4), 664-672.
18. Zhong, Y.; Meng, F.; Deng, C.; Zhong, Z. Ligand-Directed Active Tumor-Targeting Polymeric Nanoparticles for Cancer Chemotherapy. Biomacromolecules, 2014, 15(6), 1955-1969.
19. Gaertner, F. C.; Kessler, H.; Wester, H. J.; Schwaiger, M.; Beer, A. J. Radiolabelled RGD peptides for imaging and therapy. Eur. J. Nucl. Med. Mol. Imaging, 2012, 39(1), 126-138.
20. Mena, E.; Owenius, R.; Turkbey, B.; Sherry, R.; Bratslavsky, G.; Macholl, S.; Miller, M.; Somer, E.; Lindenberg, L.; Adler, S.; Shih, J.; Choyke, P.; Kurdziel, K. [18F]Fluciclatide in the in vivo evaluation of human melanoma and renal tumors expressing αVβ3 and αvβ5 integrins. Eur. J. Nucl. Med. Mol. Imaging, 2014, 41(10), 1879-1888.
21. Yang, G.; Sun, H.; Kong, Y.; Hou, G.; Han, J. Diversity of RGD radiotracers in monitoring antiangiogenesis of flavopiridol and paclitaxel in ovarian cancer xenograft-bearing mice. Nucl. Med. Biol., 2014, 41(10), 856-862.
22. Chen, K.; Chen, X. Integrin Targeted Delivery of Chemotherapeutics. Theranostics, 2011, 1, 189-200.
23. In this review, the focus is pointed to the specific functional group (here referred as "linker") that is cleaved during drug release from SMDCs.
24. Pierschbacher, M. D.; Ruoslahti, E. Cell attachment activity of fibronectin can be duplicated by small synthetic fragments of the molecule. Nature, 1984, 309(5963), 30-33.
25. Ruoslahti, E.; Pierschbacher, M. D. New perspectives in cell adhesion: RGD and integrins. Science, 1987, 238(4826), 491-497.
26. Aumailley, M.; Gurrath, M.; Muller, G.; Calvete, J.; Timpl, R.; Kessler, H. Arg-Gly-Asp constrained within cyclic pentapeptides. Strong and selective inhibitors of cell adhesion to vitronectin and laminin fragment P1. FEBS Lett., 1991, 291(1), 50-54.
27. McDowell, R. S.; Gadek, T. R. Structural studies of potent constrained RGD peptides. J. Am. Chem. Soc., 1992, 114(24), 9245- 9253.
28. Pasqualini, R.; Koivunen, E.; Ruoslahti, E. av Integrins as receptors for tumor targeting by circulating ligands. Nat. Biotech., 1997, 15(6), 542-546.
29. Xiong, J.-P.; Stehle, T.; Zhang, R.; Joachimiak, A.; Frech, M.; Goodman, S. L.; Arnaout, M. A. Crystal Structure of the Extracellular Segment of Integrin αVβ3 in Complex with an Arg-Gly-Asp Ligand. Science, 2002, 296(5565), 151-155.
30. Gottschalk, K.-E.; Kessler, H. The Structures of Integrins and Integrin- Ligand Complexes: Implications for Drug Design and Signal Transduction. Angew. Chem. Int. Ed., 2002, 41(20), 3767-3774.
31. Marchini, M.; Mingozzi, M.; Colombo, R.; Guzzetti, I.; Belvisi, L.; Vasile, F.; Potenza, D.; Piarulli, U.; Arosio, D.; Gennari, C. Cyclic RGD Peptidomimetics Containing Bifunctional Diketopiperazine Scaffolds as New Potent Integrin Ligands. Chem. Eur. J., 2012, 18(20), 6195-6207.
32. Spiegel, J.; Mas-Moruno, C.; Kessler, H.; Lubell, W. D. Cyclic Aza-peptide Integrin Ligand Synthesis and Biological Activity. J. Org. Chem., 2012, 77(12), 5271-5278.
33. Neubauer, S.; Rechenmacher, F.; Brimioulle, R.; Di Leva, F. S.; Bochen, A.; Sobahi, T. R.; Schottelius, M.; Novellino, E.; Mas- Moruno, C.; Marinelli, L.; Kessler, H. Pharmacophoric Modifications Lead to Superpotent αvβ3 Integrin Ligands with Suppressed α5β1 Activity. J. Med. Chem., 2014, 57(8), 3410-3417.
34. Auzzas, L.; Zanardi, F.; Battistini, L.; Burreddu, P.; Carta, P.; Rassu, G.; Curti, C.; Casiraghi, G. Targeting αVβ3 Integrin: Design and Applications of Mono- and Multifunctional RGD-Based Peptides and Semipeptides. Curr. Med. Chem., 2010, 17(13), 1255-1299.
35. Weis, S. M.; Stupack, D. G.; Cheresh, D. A. Agonizing Integrin Antagonists? Cancer Cell, 2009, 15(5), 359-361.
36. Shabbir, S. H.; Eisenberg, J. L.; Mrksich, M. An Inhibitor of a Cell Adhesion Receptor Stimulates Cell Migration. Angew. Chem. Int. Ed., 2010, 49(42), 7706-7709.
37. Robinson, S. D.; Hodivala-Dilke, K. M. The role of β3-integrins in tumor angiogenesis: context is everything. Curr. Opin. Cell Biol., 2011, 23(5), 630-637.
38. Reynolds, A. R.; Hart, I. R.; Watson, A. R.; Welti, J. C.; Silva, R. G.; Robinson, S. D.; Da Violante, G.; Gourlaouen, M.; Salih, M.; Jones, M. C.; Jones, D. T.; Saunders, G.; Kostourou, V.; Perron-Sierra, F.; Norman, J. C.; Tucker, G. C.; Hodivala-Dilke, K. M. Stimulation of tumor growth and angiogenesis by low concentrations of RGDmimetic integrin inhibitors. Nat. Med., 2009, 15(4), 392-400.
39. Alghisi, G. C.; Ponsonnet, L.; Ruegg, C. The Integrin Antagonist Cilengitide Activates αVβ3, Disrupts VE-Cadherin Localization at Cell Junctions and Enhances Permeability in Endothelial Cells. PLoS ONE, 2009, 4(2), e4449. doi:10.1371/journal.pone.0004449.
40. Eisele, G.; Wick, A.; Eisele, A.-C.; Clement, P.; Tonn, J.; Tabatabai, G.; Ochsenbein, A.; Schlegel, U.; Neyns, B.; Krex, D.; Simon, M.; Nikkhah, G.; Picard, M.; Stupp, R.; Wick, W.; Weller, M. Cilengitide treatment of newly diagnosed glioblastoma patients does not alter patterns of progression. J. Neurooncol., 2014, 117(1), 141-145.
41. Arap, W.; Pasqualini, R.; Ruoslahti, E. Cancer Treatment by Targeted Drug Delivery to Tumor Vasculature in a Mouse Model. Science, 1998, 279(5349), 377-380.
42. Caswell, P.; Norman, J. Endocytic transport of integrins during cell migration and invasion. Trends Cell Biol., 2008, 18(6), 257-263.
43. Caswell, P. T.; Vadrevu, S.; Norman, J. C. Integrins: masters and slaves of endocytic transport. Nat. Rev. Mol. Cell Biol., 2009, 10(12), 843-853.
44. Janssen, M.; Oyen, W. J. G.; Massuger, L. F. A. G.; Frielink, C.; Dijkgraaf, I.; Edwards, D. S.; Radjopadhye, M.; Corstens, F. H. M.; Boerman, O. C. Comparison of a Monomeric and Dimeric Radiolabeled RGD-Peptide for Tumor Targeting. Cancer Biother. Radiopharm., 2002, 17(6), 641-646.
45. Boturyn, D.; Coll, J.-L.; Garanger, E.; Favrot, M.-C.; Dumy, P. Template Assembled Cyclopeptides as Multimeric System for Integrin Targeting and Endocytosis. J. Am. Chem. Soc., 2004, 126(18), 5730-5739.
46. Choi, D. S.; Jin, H.-E.; Yoo, S. Y.; Lee, S.-W. Cyclic RGD Peptide Incorporation on Phage Major Coat Proteins for Improved Internalization by HeLa Cells. Bioconjug. Chem., 2013, 25(2), 216-223.
47. Burkhart, D. J.; Kalet, B. T.; Coleman, M. P.; Post, G. C.; Koch, T. H. Doxorubicin-formaldehyde conjugates targeting αVβ3 integrin. Mol. Cancer Ther., 2004, 3(12), 1593-1604.
48. Temming, K.; Schiffelers, R. M.; Molema, G.; Kok, R. J. RGDbased strategies for selective delivery of therapeutics and imaging agents to the tumour vasculature. Drug Resist. Update, 2005, 8(6), 381-402.
49. Chen, X.; Plasencia, C.; Hou, Y.; Neamati, N. Synthesis and Biological Evaluation of Dimeric RGD Peptide-Paclitaxel Conjugate as a Model for Integrin-Targeted Drug Delivery. J. Med. Chem., 2005, 48(4), 1098-1106; Additions and Corrections 2005, 48, 5874.
50. Cao, Q.; Li, Z.-B.; Chen, K.; Wu, Z.; He, L.; Neamati, N.; Chen, X. Evaluation of biodistribution and anti-tumor effect of a dimeric RGD peptide-paclitaxel conjugate in mice with breast cancer. Eur. J. Nucl. Med. Mol. Imaging, 2008, 35(8), 1489-1498.
51. Ryppa, C.; Mann-Steinberg, H.; Biniossek, M. L.; Satchi-Fainaro, R.; Kratz, F. In vitro and in vivo evaluation of a paclitaxel conjugate with the divalent peptide E-[c(RGDfK)2] that targets integrin αVβ3. Int. J. Pharm., 2009, 368(1-2), 89-97.
52. Colombo, R.; Mingozzi, M.; Belvisi, L.; Arosio, D.; Piarulli, U.; Carenini, N.; Perego, P.; Zaffaroni, N.; De Cesare, M.; Castiglioni, V.; Scanziani, E.; Gennari, C. Synthesis and Biological Evaluation (in vitro and in vivo) of Cyclic Arginine-Glycine-Aspartate (RGD) Peptidomimetic-Paclitaxel Conjugates Targeting Integrin αVβ3. J. Med. Chem., 2012, 55(23), 10460-10474.
53. Pilkington-Miksa, M.; Arosio, D.; Battistini, L.; Belvisi, L.; De Matteo, M.; Vasile, F.; Burreddu, P.; Carta, P.; Rassu, G.; Perego, P.; Carenini, N.; Zunino, F.; De Cesare, M.; Castiglioni, V.; Scanziani, E.; Scolastico, C.; Casiraghi, G.; Zanardi, F.; Manzoni, L. Design, Synthesis, and Biological Evaluation of Novel cRGD- Paclitaxel Conjugates for Integrin-Assisted Drug Delivery. Bioconjug. Chem., 2012, 23(8), 1610-1622.
54. Wu, H.; Chen, H.; Pan, D.; Ma, Y.; Liang, S.; Wan, Y.; Fang, Y. Imaging Integrin αVβ3 and NRP-1 Positive Gliomas with a Novel Fluorine-18 Labeled RGD-ATWLPPR Heterodimeric Peptide Probe. Mol Imaging Biol, 2014, 16(6), 781-792.
55. Lindner, S.; Michler, C.; Leidner, S.; Rensch, C.; Wangler, C.; Schirrmacher, R.; Bartenstein, P.; Wangler, B. Synthesis and in vitro and in vivo Evaluation of SiFA-Tagged Bombesin and RGD Peptides as Tumor Imaging Probes for Positron Emission Tomography. Bioconjug. Chem., 2014, 25(4), 738-749.
56. Menichetti, L.; Kusmic, C.; Panetta, D.; Arosio, D.; Petroni, D.; Matteucci, M.; Salvadori, P.; Casagrande, C.; L'Abbate, A.; Manzoni, L. MicroPET/CT imaging of αVβ3 integrin via a novel 68Ga- NOTA-RGD peptidomimetic conjugate in rat myocardial infarction. Eur. J. Nucl. Med. Mol. Imaging, 2013, 40(8), 1265-1274.
57. Dal Pozzo, A.; Ni, M.-H.; Esposito, E.; Dallavalle, S.; Musso, L.; Bargiotti, A.; Pisano, C.; Vesci, L.; Bucci, F.; Castorina, M.; Fodera, R.; Giannini, G.; Aulicino, C.; Penco, S. Novel tumor targeted RGD peptide-camptothecin conjugates: Synthesis and biological evaluation. Bioorg. Med. Chem., 2010, 18(1), 64-72.
58. Mingozzi, M.; Manzoni, L.; Arosio, D.; Dal Corso, A.; Manzotti, M.; Innamorati, F.; Pignataro, L.; Lecis, D.; Delia, D.; Seneci, P.; Gennari, C. Synthesis and biological evaluation of dual action cyclo- RGD/SMAC mimetic conjugates targeting αVβ3/αVβ5 integrins and IAP proteins. Org. Biomol. Chem., 2014, 12(20), 3288-3302.
59. Ricart, A. D. Antibody-Drug Conjugates of Calicheamicin Derivative: Gemtuzumab Ozogamicin and Inotuzumab Ozogamicin. Clin. Cancer Res., 2011, 17(20), 6417-6427.
60. Polyak, D.; Ryppa, C.; Eldar-Boock, A.; Ofek, P.; Many, A.; Licha, K.; Kratz, F.; Satchi-Fainaro, R. Development of PEGylated doxorubicin- E-[c(RGDfK)2] conjugate for integrin-targeted cancer therapy. Polym. Adv. Technol., 2011, 22(1), 103-113.
61. Choi, K. Y.; Swierczewska, M.; Lee, S.; Chen, X. Protease- Activated Drug Development. Theranostics, 2012, 2(2), 156-178.
62. Chu, D. S. H.; Johnson, R. N.; Pun, S. H. Cathepsin B-sensitive polymers for compartment-specific degradation and nucleic acid release. J. Control. Release, 2012, 157(3), 445-454.
63. Doronina, S. O.; Bovee, T. D.; Meyer, D. W.; Miyamoto, J. B.; Anderson, M. E.; Morris-Tilden, C. A.; Senter, P. D. Novel Peptide Linkers for Highly Potent Antibody-Auristatin Conjugate. Bioconjug. Chem., 2008, 19(10), 1960-1963.
64. De Groot, F. M. H.; Loos, W. J.; Koekkoek, R.; Van Berkom, L. W. A.; Busscher, G. F.; Seelen, A. E.; Albrecht, C.; de Bruijn, P.; Scheeren, H. W. Elongated Multiple Electronic Cascade and Cyclization Spacer Systems in Activatible Anticancer Prodrugs for Enhanced Drug Release. J. Org. Chem., 2001, 66(26), 8815-8830.
65. Wong, A. D.; DeWit, M. A.; Gillies, E. R. Amplified release through the stimulus triggered degradation of self-immolative oligomers, dendrimers, and linear polymers. Adv. Drug Delivery Rev., 2012, 64(11), 1031-1045.
66. de Groot, F. M. H.; Broxterman, H. J.; Adams, H. P. H. M.; van Vliet, A.; Tesser, G. I.; Elderkamp, Y. W.; Schraa, A. J.; Jan Kok, R.; Molema, G.; Pinedo, H. M.; Scheeren, H. W. Design, Synthesis, and Biological Evaluation of a Dual Tumor-specific Motive Containing Integrin-targeted Plasmin-cleavable Doxorubicin Prodrug. Mol. Cancer Ther., 2002, 1(11), 901-911.
67. Deryugina, E. I.; Quigley, J. P. Cell Surface Remodeling by Plasmin: A New Function for an Old Enzyme. J. Biomed. Biotechnol., 2012, 2012, article number 564259.
68. Rolli, M.; Fransvea, E.; Pilch, J.; Saven, A.; Felding-Habermann, B. Activated integrin αvβ3 cooperates with metalloproteinase MMP- 9 in regulating migration of metastatic breast cancer cells. Proc. Natl. Acad. Sci. USA, 2003, 100(16), 9482-9487.
69. Vartak, D. G.; Lee, B.-S.; Gemeinhart, R. A. In vitro Evaluation of Functional Interaction of Integrin αvβ3 and Matrix Metalloprotease-2. Mol. Pharm., 2009, 6(6), 1856-1867.
70. Ryppa, C.; Mann-Steinberg, H.; Fichtner, I.; Weber, H.; Satchi- Fainaro, R.; Biniossek, M. L.; Kratz, F. In vitro and in vivo Evaluation of Doxorubicin Conjugates with the Divalent Peptide E-[c(RGDfK)2] that Targets Integrin αVβ3. Bioconjug. Chem., 2008, 19(7), 1414-1422.
71. Crisp, J. L.; Savariar, E. N.; Glasgow, H. L.; Ellies, L. G.; Whitney, M. A.; Tsien, R. Y. Dual Targeting of Integrin αVβ3 and Matrix Metalloproteinase- 2 for Optical Imaging of Tumors and Chemotherapeutic Delivery. Mol. Cancer Ther., 2014, 13(6), 1514-1525.
72. Nahrwold, M.; Weis, C.; Bogner, T.; Mertink, F.; Conradi, J.; Sammet, B.; Palmisano, R.; Royo Gracia, S.; Preuse, T.; Sewald, N. Conjugates of Modified Cryptophycins and RGD-Peptides Enter Target Cells by Endocytosis. J. Med. Chem., 2013, 56(5), 1853-1864.
73. As a preliminary model, the cytotoxicity of a non-fluorescent cryptophycin- RGD conjugate bearing an "uncleavable" triazole linker was tested in Ref. [72]. The latter displayed much lower cytotoxicity compared to the free drug, highlighting once again the importance of cleavable linkers in RGD-based SMDCs.
74. Dal Pozzo, A.; Esposito, E.; Ni, M.; Muzi, L.; Pisano, C.; Bucci, F.; Vesci, L.; Castorina, M.; Penco, S. Conjugates of a Novel 7- Substituted Camptothecin with RGD-Peptides as αVβ3 Integrin Ligands: An Approach to Tumor-Targeted Therapy. Bioconjug. Chem., 2010, 21(11), 1956-1967.
75. Dal Corso, A.; Caruso, M.; Belvisi, L.; Arosio, D.; Piarulli, U.; Albanese, C.; Gasparri, F.; Marsiglio, A.; Sola, F.; Troiani, S.; Valsasina, B.; Pignataro, L.; Donati, D.; Gennari, C. Synthesis and Biological Evaluation of RGD Peptidomimetic-Paclitaxel Conjugates bearing Lysosomally Cleavable Linkers. Chem. Eur. J., 2015, 21(18), 6921-6929.
76. Liu, C.; Sun, C.; Huang, H.; Janda, K.; Edgington, T. Overexpression of Legumain in Tumors Is Significant for Invasion/Metastasis and a Candidate Enzymatic Target for Prodrug Therapy. Cancer Res., 2003, 63(11), 2957-2964.
77. Liu, Y.; Bajjuri, K. M.; Liu, C.; Sinha, S. C. Targeting Cell Surface Alpha(v)beta(3) Integrin Increases Therapeutic Efficacies of a Legumain Protease-Activated Auristatin Prodrug. Mol. Pharm., 2012, 9(1), 168-175.
78. Phillips, D. J.; Gibson, M. I. Redox-Sensitive Materials for Drug Delivery: Targeting the Correct Intracellular Environment, Tuning Release Rates, and Appropriate Predictive Systems. Antioxid. Redox Signaling, 2014, 21(5), 786-803.
79. Meister, A. Glutathione, Ascorbate, and Cellular Protection. Cancer Res., 1994, 54(7), 1969s-1975s.
80. Austin, C. D.; Wen, X.; Gazzard, L.; Nelson, C.; Scheller, R. H.; Scales, S. J. Oxidizing potential of endosomes and lysosomes limits intracellular cleavage of disulfide-based antibody-drug conjugates. Proc. Natl. Acad. Sci. U.S.A., 2005, 102(50), 17987-17992.
81. Leamon, C. P.; Vlahov, I. R.; Reddy, J. A.; Vetzel, M.; Santhapuram, H. K. R.; You, F.; Bloomfield, A.; Dorton, R.; Nelson, M.; Kleindl, P.; Vaughn, J. F.; Westrick, E. Folate-Vinca Alkaloid Conjugates for Cancer Therapy: A Structure-Activity Relationship. Bioconjug. Chem., 2014, 25(3), 560-568.
82. Lee, M. H.; Kim, J. Y.; Han, J. H.; Bhuniya, S.; Sessler, J. L.; Kang, C.; Kim, J. S. Direct Fluorescence Monitoring of the Delivery and Cellular Uptake of a Cancer-Targeted RGD Peptide- Appended Naphthalimide Theragnostic Prodrug. J. Am. Chem. Soc., 2012, 134(30), 12668-12674.
83. Thorpe, P. E.; Wallace, P. M.; Knowles, P. P.; Relf, M. G.; Brown, A. N. F.; Watson, G. J.; Knyba, R. E.; Wawrzynczak, E. J.; Blakey, D. C. New Coupling Agents for the Synthesis of Immunotoxins Containing a Hindered Disulfide Bond with Improved Stability in vivo. Cancer Res., 1987, 47(22), 5924-5931.
84. Brulisauer, L.; Gauthier, M. A.; Leroux, J.-C. Disulfide-containing parenteral delivery systems and their redox-biological fate. J. Control. Release, 2014, 195(0), 147-154.
85. Barnes, K. R.; Kutikov, A.; Lippard, S. J. Synthesis, Characterization, and Cytotoxicity of a Series of Estrogen-Tethered Platinum(IV) Complexes. Chem. Biol., 2004, 11(4), 557-564.
86. Mukhopadhyay, S.; Barnes, C. M.; Haskel, A.; Short, S. M.; Barnes, K. R.; Lippard, S. J. Conjugated Platinum(IV)-Peptide Complexes for Targeting Angiogenic Tumor Vasculature. Bioconjug. Chem., 2008, 19(1), 39-49.
87. Yuan, Y.; Kwok, R. T. K.; Zhang, R.; Tang, B. Z.; Liu, B. Targeted theranostic prodrugs based on an aggregation-induced emission (AIE) luminogen for real-time dual-drug tracking. Chem. Commun., 2014, 50(78), 11465-11468.
88. Ma, X.; Jia, J.; Cao, R.; Wang, X.; Fei, H. Histidine-Iridium(III) Coordination-Based Peptide Luminogenic Cyclization and Cyclo- RGD Peptides for Cancer-Cell Targeting. J. Am. Chem. Soc., 2014, 136(51), 17734-17737.
89. Legigan, T.; Clarhaut, J.; Tranoy-Opalinski, I.; Monvoisin, A.; Renoux, B.; Thomas, M.; Le Pape, A.; Lerondel, S.; Papot, S. The First Generation of β-Galactosidase-Responsive Prodrugs Designed for the Selective Treatment of Solid Tumors in Prodrug Monotherapy. Angew. Chem. Int. Ed., 2012, 51(46), 11606-11610.
90. Wang, X.; Ma, D.; Olsen, W. C.; Heston, W. D. W. In vitro and In vivo Responses of Advanced Prostate Tumors to PSMA ADC, an Auristatin-Conjugated Antibody to Prostate-Specific Membrane Antigen. Mol. Cancer Ther., 2011, 10(9), 1728-1739.